79 related articles for article (PubMed ID: 21528891)
1. Rational design of new class of BH3-mimetics as inhibitors of the Bcl-xL protein.
Pinto M; Orzaez Mdel M; Delgado-Soler L; Perez JJ; Rubio-Martinez J
J Chem Inf Model; 2011 Jun; 51(6):1249-58. PubMed ID: 21528891
[TBL] [Abstract][Full Text] [Related]
2. Targeting the BH3 domain mediated protein-protein interaction of Bcl-xL through virtual screening.
Mukherjee P; Desai P; Zhou YD; Avery M
J Chem Inf Model; 2010 May; 50(5):906-23. PubMed ID: 20392095
[TBL] [Abstract][Full Text] [Related]
3. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft.
Zhang YH; Bhunia A; Wan KF; Lee MC; Chan SL; Yu VC; Mok YK
J Mol Biol; 2006 Dec; 364(3):536-49. PubMed ID: 17011577
[TBL] [Abstract][Full Text] [Related]
4. Terephthalamide derivatives as mimetics of helical peptides: disruption of the Bcl-x(L)/Bak interaction.
Yin H; Lee GI; Sedey KA; Rodriguez JM; Wang HG; Sebti SM; Hamilton AD
J Am Chem Soc; 2005 Apr; 127(15):5463-8. PubMed ID: 15826183
[TBL] [Abstract][Full Text] [Related]
5. Structure and function of benzoylurea-derived alpha-helix mimetics targeting the Bcl-x(L)/Bak binding interface.
Rodriguez JM; Ross NT; Katt WP; Dhar D; Lee GI; Hamilton AD
ChemMedChem; 2009 Apr; 4(4):649-56. PubMed ID: 19330783
[TBL] [Abstract][Full Text] [Related]
6. Relaxation of the rigid backbone of an oligoamide-foldamer-based α-helix mimetic: identification of potent Bcl-xL inhibitors.
Yap JL; Cao X; Vanommeslaeghe K; Jung KY; Peddaboina C; Wilder PT; Nan A; MacKerell AD; Smythe WR; Fletcher S
Org Biomol Chem; 2012 Apr; 10(15):2928-33. PubMed ID: 22395339
[TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR pharmacophore modeling and in silico screening of new Bcl-xl inhibitors.
Almerico AM; Tutone M; Lauria A
Eur J Med Chem; 2010 Nov; 45(11):4774-82. PubMed ID: 20728251
[TBL] [Abstract][Full Text] [Related]
8. Terphenyl-Based Bak BH3 alpha-helical proteomimetics as low-molecular-weight antagonists of Bcl-xL.
Yin H; Lee GI; Sedey KA; Kutzki O; Park HS; Orner BP; Ernst JT; Wang HG; Sebti SM; Hamilton AD
J Am Chem Soc; 2005 Jul; 127(29):10191-6. PubMed ID: 16028929
[TBL] [Abstract][Full Text] [Related]
9. A new assay for the discovery of Bcl-XL inhibitors.
Pisoni C; Cimoli G; Resconi A; Losi D; Lorenzetti R; Parodi S; Carrano L
Farmaco; 2005; 60(11-12):938-43. PubMed ID: 16054143
[TBL] [Abstract][Full Text] [Related]
10. Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions.
Finnegan NM; Curtin JF; Prevost G; Morgan B; Cotter TG
Br J Cancer; 2001 Jul; 85(1):115-21. PubMed ID: 11437412
[TBL] [Abstract][Full Text] [Related]
11. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis.
Petros AM; Dinges J; Augeri DJ; Baumeister SA; Betebenner DA; Bures MG; Elmore SW; Hajduk PJ; Joseph MK; Landis SK; Nettesheim DG; Rosenberg SH; Shen W; Thomas S; Wang X; Zanze I; Zhang H; Fesik SW
J Med Chem; 2006 Jan; 49(2):656-63. PubMed ID: 16420051
[TBL] [Abstract][Full Text] [Related]
12. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions.
Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH
J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293
[TBL] [Abstract][Full Text] [Related]
13. Biochemical and pharmacological profiling of the pro-survival protein Bcl-xL.
Goreshnik I; Brock AM; Maly DJ
Bioorg Med Chem Lett; 2011 Sep; 21(17):4951-5. PubMed ID: 21807512
[TBL] [Abstract][Full Text] [Related]
14. A conserved hydrophobic core at Bcl-xL mediates its structural stability and binding affinity with BH3-domain peptide of pro-apoptotic protein.
Feng Y; Zhang L; Hu T; Shen X; Ding J; Chen K; Jiang H; Liu D
Arch Biochem Biophys; 2009 Apr; 484(1):46-54. PubMed ID: 19161970
[TBL] [Abstract][Full Text] [Related]
15. Interaction of a putative BH3 domain of clusterin with anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy.
Lee DH; Ha JH; Kim Y; Bae KH; Park JY; Choi WS; Yoon HS; Park SG; Park BC; Yi GS; Chi SW
Biochem Biophys Res Commun; 2011 May; 408(4):541-7. PubMed ID: 21527247
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and interaction study of quinazoline-2(1H)-thione derivatives as novel potential Bcl-xL inhibitors.
Feng Y; Ding X; Chen T; Chen L; Liu F; Jia X; Luo X; Shen X; Chen K; Jiang H; Wang H; Liu H; Liu D
J Med Chem; 2010 May; 53(9):3465-79. PubMed ID: 20405848
[TBL] [Abstract][Full Text] [Related]
17. Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands.
Kvansakul M; Yang H; Fairlie WD; Czabotar PE; Fischer SF; Perugini MA; Huang DC; Colman PM
Cell Death Differ; 2008 Oct; 15(10):1564-71. PubMed ID: 18551131
[TBL] [Abstract][Full Text] [Related]
18. Oligomerization of BH4-truncated Bcl-x(L) in solution.
Wang Y; Cao R; Liu D; Chervin A; Yuan J; An J; Huang Z
Biochem Biophys Res Commun; 2007 Oct; 361(4):1006-11. PubMed ID: 17692289
[TBL] [Abstract][Full Text] [Related]
19. Deciphering the antitumoral activity of quinacrine: Binding to and inhibition of Bcl-xL.
Orzáez M; Mondragón L; García-Jareño A; Mosulén S; Pineda-Lucena A; Pérez-Payá E
Bioorg Med Chem Lett; 2009 Mar; 19(6):1592-5. PubMed ID: 19237284
[TBL] [Abstract][Full Text] [Related]
20. Photocontrollable peptide-based switches target the anti-apoptotic protein Bcl-xL.
Kneissl S; Loveridge EJ; Williams C; Crump MP; Allemann RK
Chembiochem; 2008 Dec; 9(18):3046-54. PubMed ID: 19012295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
